All major GLP-1 medications referenced on this site — tirzepatide forms (the focus of this site) plus comparison-class semaglutide, liraglutide, and dulaglutide.
This reference catalogs every GLP-1 receptor agonist commonly available in the United States in 2026, organized by active ingredient and brand. The focus of this site is tirzepatide and its forms (Mounjaro, Zepbound, compounded tirzepatide), but the comparison-class medications — semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity) — are included because clinical and treatment decisions are made by comparison across the class.
Tirzepatide (Mounjaro/Zepbound) consistently produces the most weight loss in the GLP-1 class to date, with SURMOUNT-1 showing mean 20.9% body weight loss at 15 mg over 72 weeks. SURMOUNT-5 directly demonstrated superiority over semaglutide 2.4 mg in adults with obesity.
Semaglutide (Wegovy) has the most robust cardiovascular outcomes data, with the SELECT trial (2023) demonstrating a 20% reduction in major adverse cardiovascular events in adults with established CVD and overweight or obesity without diabetes. This led to Wegovy's March 2024 FDA approval for cardiovascular risk reduction.
Yes — Rybelsus (oral semaglutide) is the only oral GLP-1 receptor agonist available in the US, FDA-approved for type 2 diabetes. It requires strict administration: 30 minutes before the first food, drink, or medications of the day, with no more than 4 ounces of plain water.
Same active ingredient (tirzepatide), same manufacturer (Eli Lilly), but different FDA-approved labels. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and moderate-to-severe obstructive sleep apnea in obesity. Insurance coverage pathways and prescribing decisions depend on the patient's diagnosis.